Supplementary information to the article "Integrating phenotypic search and phosphoproteomic profiling of active kinases for optimization of drug mixtures for RCC treatment". Judy R. van Beijnum1, Andrea Weiss2, 3, Robert H. Berndsen1,2 , Tse J. Wong1, Louise C. Reckman1, Sander R. Piersma4,5, Marloes Zoetemelk2,3, Richard de Haas1,4,5, Olivier Dormond6, Axel Bex7,8, Alexander A. Henneman4,5, Connie R. Jimenez4,5, Arjan W. Griffioen1, Patrycja Nowak-Sliwinska2,3,9* 1 Angiogenesis Laboratory, Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Medical Oncology, Cancer Center Amsterdam, De Boelelaan 1117, Amsterdam, Netherlands; 2 Molecular Pharmacology Group, School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland*; 3 Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland 4 Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Medical Oncology, Cancer Center Amsterdam, De Boelelaan 1117, Amsterdam, Netherlands 5 OncoProteomics Laboratory, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands 6 Department of Visceral surgery, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland 7 Royal Free London NHS Foundation Trust, Renal Cancer Centre, UCL Division of Surgical and Interventional Science, London, UK 8 Netherlands Cancer Institute, Amsterdam, The Netherlands 9 Translational Research Centre in Oncohaematology, Geneva, Switzerland Correspondence: Patrycja.Nowak-Sliwinska@unige.ch